Abstract
This white paper treats liver-chip validation as an investment in a specific development decision, not a blanket endorsement of alternative testing platforms. Regulatory terminology and retrospective liver-chip research provide context for a more disciplined validation question. The historical benchmark included 870 chips and 27 small molecules, but its classification results cannot be assumed to predict patient outcomes or a new program's prospective performance. A transparent hypothetical model compares the cost of validating an additional liver-toxicity screen against expected error costs and potential delay. Under its stated assumptions, a longer gate can reverse the modeled economic benefit. The practical recommendation is to define intended use, pre-agree validation thresholds, test transferability, document inconclusive results and identify what management will do if the evidence is favorable, uncertain or negative. No regulatory qualification or patient benefit is implied.
Read the complete research: Liver-chip validation: the evidence and investment gate for a NAM.